Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 18/20 | 0.52 |
| ▸ | PIK3CA | P42336 | 13/20 | 0.52 |
| ▸ | PIK3CD | O00329 | 13/20 | 0.52 |
| ▸ | PIK3CB | P42338 | 11/20 | 0.52 |
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 0.40 |
| ▸ | AKT1 | P31749 | 1/20 | 0.40 |
| ▸ | MTOR | P42345 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4197749 | 0.87 | PIK3CG (0.53) | PIK3CGPIK3CAPIK3CDPIK3CBPIK3C3 | |
| SCHEMBL4206088 | 0.83 | PIK3CG (0.55) | PIK3CGPIK3CAPIK3CDPIK3CBPIK3C3 | |
| SCHEMBL4202210 | 0.81 | PIK3CG (0.51) | PIK3CGPIK3CAPIK3CDPIK3CB | |
| SCHEMBL923907 | 0.80 | PIK3CG (0.63) | PIK3CGPIK3CAPIK3CDPIK3CB | |
| SCHEMBL4208416 | 0.79 | PIK3CG (0.59) | PIK3CGPIK3CAPIK3CDPIK3CBPIK3C3 | |
| SCHEMBL4208541 | 0.78 | PIK3CG (0.51) | PIK3CGPIK3CAPIK3CDPIK3CBPIK3C3 | |
| SCHEMBL4213919 | 0.77 | PIK3CG (0.47) | PIK3CGPIK3CAPIK3CDPIK3CBPIK3C3 | |
| SCHEMBL4201639 | 0.77 | PIK3CG (0.47) | PIK3CGPIK3CAPIK3CDPIK3CBPIK3C3 | |
| SCHEMBL4210698 | 0.76 | PIK3CG (0.53) | PIK3CGPIK3CAPIK3CDPIK3CBPIK3C3 | |
| SCHEMBL4205705 | 0.75 | PIK3CG (0.47) | PIK3CGPIK3CAPIK3CDPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090029997-A1 | Thiazole Derivatives and Use Thereof | LABORATOIRES SERONO SA (CH) | 2009-01-29 | — | — | US | claimed |
| EP-1979346-A1 | THIAZOLE DERIVATIVES AND USE THEREOF | LABORATOIRES SERONO S.A. (CH) | 2008-10-15 | — | — | EP | claimed |
| WO-2007082956-A1 | THIAZOLE DERIVATIVES AND USE THEREOF | LABORATOIRES SERONO S.A. (CH) | 2007-07-26 | — | — | WO | claimed |
| US-20090029997-A1 | Thiazole Derivatives and Use Thereof | LABORATOIRES SERONO SA (CH) | 2009-01-29 | — | — | US | disclosed |
| US-20090029997-A1 | Thiazole Derivatives and Use Thereof | LABORATOIRES SERONO SA (CH) | 2009-01-29 | — | — | US | disclosed |
| US-20090029997-A1 | Thiazole Derivatives and Use Thereof | LABORATOIRES SERONO SA (CH) | 2009-01-29 | — | — | US | disclosed |
| WO-2007082956-A1 | THIAZOLE DERIVATIVES AND USE THEREOF | LABORATOIRES SERONO S.A. (CH) | 2007-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029997-A1 | Thiazole Derivatives and Use Thereof | PDGFRB, PDGFRA, TEC | PIK3CG 2526/4885PIK3CA 1647/4885PIK3CD 1844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.